A new series of hybrid PDMP analogues, based both on PDMP and styryl analogues of natural ceramide, has been synthesised from D-serine. The synthetic route was developed such that future introduction of different aryl groups is straightforward. Biological evaluation, both in vitro on rat liver Golgi fractions as well as in HEK-293 and COS-7 cells, revealed two lead compounds with comparable inhibitory potency as PDMP, which could be elaborated to more potent inhibitors.
(R)-tert-Butyl 4-((R)-1'-hydroxy-3'-(trimethylsilyl)prop-2'-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (threo-4)
To a solution of trimethylsilylacetylene (12.53 mL, 88 mmol, 1.66 eq.) in anhydrous Et 2 O (450 mL) at -78°C, nBuLi (50 mL of 1.6M in hexanes, 80 mmol, 1.51 eq.) was added dropwise. The mixture was stirred for 1 h at 0°C and 1 h at room temperature and was subsequently cooled to 0°C. After addition of ZnBr 2 (23.89 g, 106.1 mmol, 2 eq.), the reaction mixture was stirred at room temperature for 1 h and subsequently cooled to -78°C.
D-Garner's aldehyde (12. 16 g, 53.07 mmol) was dissolved in anhydrous Et 2 O (50 mL), cooled to -78°C and added dropwise to the above solution. The mixture was allowed to reach room temperature overnight and after cooling to 0°C, saturated NH 4 Cl (100 mL) was added in one portion. The aqueous layer was extracted with Et 2 O (2 x 100 mL). The combined organic phase was dried over MgSO 4 , and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (hexanes:EtOAc 9:1) affording threo-4 (7.167 g, 41%) and a mixture of erythro/threo-4 (4.736 g, 27%), both as a slightly yellow oil. 
(R)-tert-Butyl 4-((R)-1'-hydroxyprop-2'-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (5a)
TBAF (38.5 mL of a 1M solution in THF, 38.5 mmol, 1.2 eq.) was added to a solution of threo-4 (10.5 g, 32.05 mmol) in THF (10 mL). The solution was stirred for 1 h at room temperature and the solvent was subsequently removed under reduced pressure. The residue was dissolved in EtOAc (50 mL) and washed with saturated NaHCO 3 (50 mL). The aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic phase was dried over MgSO 4 and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (hexanes:EtOAc 4:1) yielding threo-5a (7.61 g, 93%) as a white solid. 
(R)-tert-Butyl 4-((R
)
tert-Butyl (2R,3R)-1,3-dihydroxypent-4-yn-2-ylcarbamate (6a)
A solution of threo-5a (7.57 g, 29.65 mmol) in 90% acetic acid was stirred for 5 h at 60°C.
The solvent was removed under reduced pressure, and the residue was coevaporated twice with isooctane (25 mL). The residue was purified by flash chromatography (hexanes:EtOAc afforded 8a and 8b as colourless oils. General procedure for the preparation of alcohols 9a and 9b. To a solution of 8a or 8b
(4S,5R)-tert-Butyl 5-ethynyl-4-((tert-butyldiphenylsilyloxy)methyl)-2,2-
(10 mmol) in THF (50 mL), TBAF (15 mmol) was added in one portion, and the solution was stirred for 75 min at room temperature. The solvent was subsequently removed under reduced pressure, and the residue was dissolved in EtOAc (100 mL). The organic layer was washed with saturated NaHCO 3 (3 x 25 mL), dried over MgSO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (hexanes:EtOAc 4:1) yielding 9a and 9b as white solids. General procedure for the preparation of tosylates 10a and 10b. Solid p-TsCl (3 mmol) was added to an ice-cold solution of 9a or 9b (1 mmol) in anhydrous pyridine (1 mL) and after stirring for 35 h at room temperature, the reaction mixture was evaporated to dryness at high vacuum (< 35°C for 10a, 40 -50°C for 10b). The residue was purified by column chromatography (hexanes:EtOAc 85:15) to yield 10a and 10b as white solids.
(4R,5R)-tert-Butyl 5-ethynyl-4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (9a)

g (96%
((4R,5R)-3-(tert-Butoxycarbonyl)-5-ethynyl-2,2-dimethyloxazolidin-4-yl)methyl
4-methylbenzenesulfonate (10a) 
g (94%
((4R,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-5-(2-phenylethynyl)oxazolidin-4-yl)methyl 4-methylbenzenesulfonate (10b)
128 mg (64% 
(4R,5R)-tert-Butyl 4-(azidomethyl)-2,2-dimethyl-5-(2-phenylethynyl)oxazolidine-
3-carboxylate (11e)
NaN 3 (268 mg, 4.12 mmol, 10 eq.) was added to a solution of 10b (200 mg, 0.412 mmol) in anhydrous DMF (10 mL) and the mixture was heated at 45°C for 72 h. 
N-((2R,3R)-3-Hydroxy-1-morpholino-5-phenylpent-4-yn-2-yl)palmitamide (13a)
232 mg (67% 
4.1.21.
N-((2R,3R)-3-Hydroxy-5-phenyl-1-(piperidin-1-yl)pent-4-yn-2-yl)palmitamide (13b)
227 mg (48% 
N-((2R,3R)-3-Hydroxy-5-phenyl-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide (13c)
129 mg (45% Sonogashira coupling of 18 with iodobenzene. An identical procedure as for the conversion of 9a to 9b gave 13c (19 mg, 32%) as a colourless solid.
N-((2R,3R)-1-Azido-3-hydroxy-5-phenylpent-4-yn-2-yl)palmitamide (13d)
351 mg (62% 455.3380.
N-((2R,3R)-3-Hydroxy-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide (18)
71 mg (60% 
N-((2R
,
(E,3R,4R)-4-(Hexadecylamino)-5-morpholino-1-phenylpent-1-en-3-ol (14a)
115 mg (60% 
In vitro analysis of GlcCer synthase
In vitro analysis of GlcCer synthase was performed in rat Golgi membranes using N- 
Analysis of GlcCer synthase activity in living cells
Human embryonic kidney HEK-293 cells were grown to 80-90% confluency. C6-NBD-Derythro-Ceramide was added directly to the culture dishes, together with 10, 25, and 50 µM of inhibitors. Cells were incubated for 3 hours at 37°C in a 5% CO 2 incubator. At the end of the incubation, dishes were washed with PBS, and cells removed by scraping with a rubber stirring rod into ice-cold water. Lipids were extracted, 20 separated and quantified as above.
3 H-serine labeling
Dishes, containing HEK-293 and COS-7 cells, were incubated for 1 hour with 50 mM of compounds 18 and 16c, followed by addition of L-[3-3 H]-serine (Amersham) (30 µCi in 3 ml medium) for another 3 hours. At the end of the incubation, dishes were washed with PBS, cells removed by scraping with a rubber stirring rod into ice-cold water, and lipids extracted. 20 Phospholipids were degraded by mild alkaline hydrolysis with methanolic NaOH (100mM) for 2 h at 37°C. Lipid extracts were desalted by Sephadex G-25 (superfine, Sigma), 21 and separated by TLC using chloroform/methanol/9.8 mM CaCl 2 (60:35:8, v/v/v) as the developing solvent. Sphingolipids were visualized by spraying with cupric sulfate, followed by brief charring. Ceramide, glucosylceramide, lactosylceramide, and sphingomyelin were identified using authentic standards. Corresponding bands were scraped from the TLC plates, radioactivity was recovered from silica in 1 ml of methanol, followed by addition of Ultima Gold scintillation cocktail. Radioactivity was determined by liquid scintillation counting. 
